Abstract
The common structural requirements for cytotoxicity of lamellarins against two human breast cancer cell lines were determined using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques. Twenty lamellarins were selected to serve as the training set, whereas another group of six compounds were used as the test set. The best CoMFA and CoMSIA models for both cell lines yielded satisfactory predictive ability with r 2cv values in the range of 0.659–0.728. Additionally, the contour maps obtained from both the CoMFA and CoMSIA models agreed well with the experimental results and may be used in the design of more potent cytotoxic compounds for human breast cancers. Both analyses not only suggested structural requirements of various substituents around the lamellarin skeleton for their cytotoxic activity against both human breast cancer cell lines but also revealed the molecular basis for the differences between the saturated and unsaturated D-rings of the lamellarins.
Graphical Abstract
Similar content being viewed by others
References
Andersen RJ, Faulkner DJ, He CH, Van Duyne GD, Clardy J (1985) J Am Chem Soc 107:5492
Carroll AR, Bowden BF, Coll JC (1993) Aust J Chem 46:489
Davis RA, Carroll AR, Pierens GK, Quinn RJ (1999) J Nat Prod 62:419
Ham J, Kang H (2002) Bull Korean Chem Soc 23:163
Krishnaiah P, Reddy VLN, Venkataramana G, Ravinder K, Srinivasulu M, Raju TV, Ravikumar K, Chandrasekar D, Ramakrishna S, Venkateswarlu Y (2004) J Nat Prod 67:1168
Lindquist N, Fenical W, Van Duyne GD, Clardy J (1988) J Org Chem 53:4570
Reddy MVR, Faulkner DJ, Venkateswarlu Y, Rao MR (1997) Tetrahedron 53:3457
Reddy SM, Srinivasulu M, Satyanarayana N, Kondapi AK, Venkateswarlu Y (2005) Tetrahedron 61:9242
Urban S, Butler MS, Capon RJ (1994) Aust J Chem 47:1919
Urban S, Capon RJ (1996) Aust J Chem 49:711
Urban S, Hobbs L, Hooper JNA, Capon RJ (1995) Aust J Chem 48:1491
Reddy MVR, Rao MR, Rhodes D, Hansen MST, Rubins K, Bushman FD, Venkateswarlu Y, Faulkner DJ (1999) J Med Chem 42:901
Ridley CP, Reddy MVR, Rocha G, Bushman FD, Faulkner DJ (2002) Bioorg Med Chem 10:3285
Fan H, Peng J, Hamann MT, Hu JF (2008) Chem Rev 108:264
Facompre M, Tardy C, Bal-Mahieu C, Colson P, Perez C, Manzanares I, Cuevas C, Bailly C (2003) Cancer Res 63:7392
Vanhuyse M, Kluza J, Tardy C, Otero G, Cuevas C, Bailly C, Lansiaux A (2005) Cancer Lett 221:165
Costantini P, Jacotot E, Decaudin D, Kroemer G (2000) J Natl Cancer Inst 92:1042
Debatin KM, Poncet D, Kroemer G (2002) Oncogene 21:8786
Dias N, Bailly C (2005) Biochem Pharmacol 70:1
Kluza J, Gallego MA, Loyens A, Beauvillain JC, Sousa-Faro JMF, Cuevas C, Marchetti P, Bailly C (2006) Cancer Res 66:3177
Mayer AMS, Gustafson KR (2008) Eur J Cancer 44:2357
Baunbaek D, Trinkler N, Ferandin Y, Lozach O, Ploypradith P, Rucirawat S, Ishibashi F, Iwao M, Meijer L (2008) Mar Drugs 6:514
Quesada AR, Garcia Gravalos MD, Fernandez Puentes JL (1996) Br J Cancer 74:677
Bailly C (2004) Curr Med Chem Anticancer Agents 4:363
Ishibashi F, Tanabe S, Oda T, Iwao M (2002) J Nat Prod 65:500
Marco E, Laine W, Tardy C, Lansiaux A, Iwao M, Ishibashi F, Bailly C, Gago F (2005) J Med Chem 48:3796
Chittchang M, Batsomboon P, Ruchirawat S, Ploypradith P (2009) ChemMedChem 4:457
Thipnate P, Liu J, Hannongua S, Hopfinger AJ (2009) J Chem Inf Model 49:2312
Ploypradith P, Petchmanee T, Sahakitpichan P, Litvinas ND, Ruchirawat S (2006) J Org Chem 71:9440
Bohm M, Sturzebecher J, Klebe G (1999) J Med Chem 42:458
Cramer RD III, Patterson DE, Bunce JD (1988) J Am Chem Soc 110:5959
Klebe G, Abraham U, Mietzner T (1994) J Med Chem 37:4130
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA Jr, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA (2004) Gaussian 03. Gaussian Inc., Wallingford
Acknowledgments
This work would not have been possible without generous support from the Chulabhorn Research Institute (CRI), the Chulabhorn Graduate Institute (CGI), Phetchaburi Rajabhat University (PBRU), the Kasetsart University (KU) Graduate School, and the Commission on Higher Education (CHE). The Thailand Research Fund (TRF) is gratefully acknowledged for research grants (RTA5080005 to S.H., BRG5180013 to P.P., RMU4980048 to N.T., and DBG5180015 to M.C.). Moreover, the authors would like to thank the National Center of Excellence in Petroleum, Petrochemicals, and Advanced Materials, KU Research and Development Institute (KURDI), Laboratory for Computational and Applied Chemistry (LCAC) and the computing centre of KU, the Center of Nanotechnology KU, NANOTEC Center of Excellence at KU, and the Large Scale Research Laboratory of the National Electronics and Computer Technology (NECTEC) for computing and research facilities.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thipnate, P., Chittchang, M., Thasana, N. et al. Exploring the molecular basis for selective cytotoxicity of lamellarins against human hormone-dependent T47D and hormone-independent MDA-MB-231 breast cancer cells. Monatsh Chem 142, 97–109 (2011). https://doi.org/10.1007/s00706-010-0409-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00706-010-0409-y